Table of Contents Author Guidelines Submit a Manuscript
Obstetrics and Gynecology International
Volume 2010, Article ID 682504, 7 pages
Research Article

Hypermethylation of SOX2 Promoter in Endometrial Carcinogenesis

1Department of Pathology, Queen Mary Hospital, The University of Hong Kong, Pokfulam Road, Hong Kong
2Department of Pathology, Peking Union Medical College Hospital, CAMS and PUMC, Beijing 100730, China

Received 20 November 2009; Revised 4 June 2010; Accepted 7 July 2010

Academic Editor: Fan Jin

Copyright © 2010 Oscar Gee-Wan Wong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


This paper aimed at investigating the expression and methylation profiles of SOX2, a gene coding for the stem cell-related transcription factor SOX2, in endometrial carcinomas. By methylation-specific polymerase chain reaction (MS-PCR), the methylation status of SOX2 promoter region in 72 endometrial carcinomas and 12 normal endometrial samples was examined. Methylated allele was found in 37.5% (27/72) of endometrial carcinomas but only in 8.3% (1/12) of normal endometrial, significantly more frequent in cancers ( 𝑃 = . 0 4 7 2 ). SOX2 mRNA level was significantly reduced in endometrial carcinoma compared with nonneoplastic endometrium ( 𝑃 = . 0 4 5 ). A significant correlation between SOX2 mRNA expression and hypermethylation of SOX2 was found ( 𝑃 = . 0 2 4 ). Hypermethylation of SOX2 tended to be more frequently found in type II serous or clear cell adenocarcinoma. SOX2 methylation was also significantly correlated with shorter survival of patients ( 𝑃 = . 0 4 6 ). In conclusion, epigenetic mechanisms may play a crucial role on the transcriptional regulation of SOX2 and loss of SOX2 expression may be related to endometrial carcinogenesis.